Sign in to view content

Baseline DR Severity and Time to DME Resolution in Patients Treated With Ranibizumab in the RIDE and RISE Clinical Trials

Katherine E Talcott, MD

Video
Published 2021

Related

48-Week End of Study Results From BEHOLD Phase 2 Study of UBX1325 in Patients With DME
Arshad M. Khanani, MD, MA, FASRS
Annual Meeting Talks
2023
Subretinal Aflibercept vs Ranibizumab vs Bevacizumab in the Context of PPV: Pneumatic Displacement With Subretinal Air and tPA in Naïve Submacular Hemorrhage Due to nAMD
Matias Iglicki, MD
Annual Meeting Talks
2024
Diabetic Retinopathy and the MyVisionTrack App Study (DRAMA)
Samuel K. Steven Houston, MD, FASRS
On Demand Cases, Courses, and Papers
2017

Category: Diabetic Retinopathy

See more